Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00394147 · ClinicalTrials.gov registry record · Phase 2
Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer
A Phase 2 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00394147 is a Phase 2 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 17 participants.
The verdict
NCT00394147, a Phase 2 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to look at how well the combination of two chemotherapy drugs, pemetrexed (Alimta) and gemcitabine (Gemzar) work to treat your cancer.
Interventions
- DRUG pemetrexed
- DRUG gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00394147
The ClinicalTrials.gov registry entry for NCT00394147 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pemetrexed is the first listed.
NCT00394147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00394147 about?
NCT00394147 is a clinical study titled "Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer". The purpose of this study is to look at how well the combination of two chemotherapy drugs, pemetrexed (Alimta) and gemcitabine (Gemzar) work to treat your cancer.
What is the current status of trial NCT00394147?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2006-10. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00394147?
The interventions under investigation include: pemetrexed (DRUG), gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00394147?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.